Travere Therapeutics, Inc.

NasdaqGM:TVTX Stock Report

Market Cap: US$1.3b

Travere Therapeutics Future Growth

Future criteria checks 6/6

Travere Therapeutics is forecast to grow earnings and revenue by 64.5% and 26.4% per annum respectively. EPS is expected to grow by 65% per annum. Return on equity is forecast to be 242.5% in 3 years.

Key information

64.5%

Earnings growth rate

65.03%

EPS growth rate

Biotechs earnings growth23.8%
Revenue growth rate26.4%
Future return on equity242.47%
Analyst coverage

Good

Last updated21 May 2025

Recent future growth updates

Recent updates

Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt?

May 29
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt?
author-image

Expanded Approvals Will Broaden IgAN And FSGS Treatment Options

FILSPARI's expanded approval and ongoing studies position it for increased revenue from treating renal diseases, with potential market expansion from the new sNDA submission for FSGS.

Revenues Working Against Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Following 26% Dive

Apr 11
Revenues Working Against Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Following 26% Dive

Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade

Mar 07

Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts

Feb 14
Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shareholders Might Be Looking For Exit

Feb 06
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shareholders Might Be Looking For Exit

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dec 19

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Oct 31
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Oct 07
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 30

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Sep 10
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22
Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08
New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05
It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 16
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Oct 13

Earnings and Revenue Growth Forecasts

NasdaqGM:TVTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027742207401-249
12/31/2026568391313114
12/31/2025397-996-5714
3/31/2025274-226-267-161N/A
12/31/2024233-321-339-237N/A
9/30/2024203-349-369-272N/A
6/30/2024178-383-382-289N/A
3/31/2024156-416-338-318N/A
12/31/2023145-376-322-280N/A
9/30/2023130-373-305-264N/A
6/30/2023120-368-288-245N/A
3/31/202392-352-263-212N/A
12/31/2022109-331-215-186N/A
9/30/2022137-297-188-159N/A
6/30/2022178-249-114-87N/A
3/31/2022229-202-64-44N/A
12/31/2021132-217-39-15N/A
9/30/2021221-250-29-2N/A
6/30/2021204-237-56-27N/A
3/31/2021198-224-69-40N/A
12/31/2020198-169-67-43N/A
9/30/2020194-78-53-33N/A
6/30/2020187-92-71-54N/A
3/31/2020184-105-83-67N/A
12/31/2019175-146-74-58N/A
9/30/2019172-124-73-57N/A
6/30/2019169-142-62-47N/A
3/31/2019165-125-46-31N/A
12/31/2018164-103N/A-25N/A
9/30/2018163-113N/A-22N/A
6/30/2018162-76N/A-12N/A
3/31/2018160-67N/A-4N/A
12/31/2017155-60N/A7N/A
9/30/2017150-51N/A0N/A
6/30/2017144-70N/A-2N/A
3/31/2017138-70N/A-3N/A
12/31/2016134-48N/A-3N/A
9/30/2016127-42N/A2N/A
6/30/2016121101N/A-2N/A
3/31/201611289N/A2N/A
12/31/2015100117N/A-1N/A
9/30/20158491N/A-7N/A
6/30/201564-33N/A-23N/A
3/31/2015464N/A-43N/A
12/31/201428-111N/A-46N/A
9/30/201414-95N/A-45N/A
6/30/20146-89N/A-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TVTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: TVTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TVTX is expected to become profitable in the next 3 years.

Revenue vs Market: TVTX's revenue (26.4% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: TVTX's revenue (26.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TVTX's Return on Equity is forecast to be very high in 3 years time (242.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/06 06:47
End of Day Share Price 2025/06/06 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Travere Therapeutics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guyn KimBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Dae Gon HaBTIG